AmbioPharm Inc. Expands Peptide Production Helping Fight Against Covid-19
AmbioPharm Inc. a leading supplier of peptide active pharmaceutical ingredients has recently opened its new manufacturing and quality control facilities at its headquarters in South Carolina. “The new buildings were completed in April and qualified by May 15, 2020 expanding our peptide manufacturing capacity,” stated Dr. Chris J. Bai, CEO. “The new buildings add nearly 56,000 sq. ft of production space to our current footprint in South Carolina. In the near future, our subsidiary site in Shanghai will also complete a new campus of 350,000 sq. ft. later this year,” stated Dr. Bai.
“As the world battles the Covid-19 pandemic, it has become increasingly apparent that no single solution will suffice for patients who are fighting the disease. Peptide approaches have been recently advanced for potential vaccine development, diagnostic testing and as therapeutic agents to help ameliorate the cytokine storm,” stated Dr. Michael W. Pennington, CSO. “Furthermore, we believe that science will prove to be the Achilles’ heel of the virus, and the world will recover more quickly as better therapies become available,” added Dr. Pennington.
AmbioPharm Inc. is uniquely positioned to help companies that are developing peptide-based approaches targeting the virus. As the company with the world’s largest cGMP peptide manufacturing capacity, AmbioPharm Inc. has a very unique business model which helps us to produce peptides of both high quality and purity with very economical cost. AmbioPharm Inc. can be contacted through our website if you have a project which requires our services.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global Expands in the Caribbean2.7.2020 15:30:00 CEST | Press release
Andersen Global announced it entered into a Collaboration Agreement with San Juan, Puerto Rico-based, full-service tax firm BDO Tax LLC, marking the organization’s debut in the region. Founded in 2000, BDO Tax LLC is led by Managing Partner Gaby Hernandez and supported by more than 140 professionals. It provides an array of tax and business advisory services to more than 3,000 clients, including transfer pricing, private client services, transaction advisory, government contracting, accounting services and tax compliance with a specific focus on international tax and inbound tax advisory. “As a former Arthur Andersen professional, I appreciate the importance and impact of working with like-minded individuals who share similar values and commitment to their clients,” Gaby said. “Collaborating with Andersen Global enhances our ability to deliver seamless coverage globally and provide a more comprehensive range of services.” “Gaby has built one of the strongest practices in the region and
Skilling lanserar MT42.7.2020 15:10:00 CEST | Pressmeddelande
Forex- och CFD-handelsplattformen Skilling nådde ytterligare en viktig milstolpe i år med integrationen och lanseringen av handelsplattformen MetaTrader 4 (MT4). Detta pressmeddelande använder multimedia. Se den fullständiga versionen här: https://www.businesswire.com/news/home/20200702005313/sv/ Skilling lanserar MT4 (Photo: Business Wire) Skilling grundades 2016 och introducerade sin egen handelsplattform 2018. I januari 2020 tillkännagav de lanseringen av branschens första sömlösa integration med Spotware cTrader. Med deras förvärv av en licens från FSA Seychellerna tidigare i år kan Skilling nu erbjuda MT4 till sina nuvarande och nya kunder på global nivå. ”Vi har arbetat outtröttligt för att lansera den berömda MetaTrader 4, även känd som MT4, den elektroniska handelsplattformen som allmänt används av investerare runt om i världen. Idag är vi stolta över att äntligen kunna erbjuda våra kunder en mycket anpassningsbar plattform med många avancerade verktyg och funktioner, till exem
Zynga Closes Transformational Acquisition of Istanbul-based Peak; Expands Forever Franchise Portfolio with Toon Blast and Toy Blast2.7.2020 15:05:00 CEST | Press release
Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, and Peak, Istanbul-based creator of Toon Blast and Toy Blast, announced today that the companies have closed the transaction under which Zynga acquired all of the issued and outstanding common shares of Peak for a total purchase price of approximately $1.85 billion comprised approximately of equal contributions of cash and Zynga common stock. Peak brings to Zynga a renowned, talented team and two forever franchises, Toon Blast and Toy Blast, that have consistently ranked within the top 10 and top 20 U.S. iPhone grossing games for the past two years, respectively. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200702005008/en/ Zynga Closes Transformational Acquisition of Istanbul-based Peak; Expands Forever Franchise Portfolio with Toon Blast and Toy Blast (Graphic: Business Wire) Peak will continue to be led by founder and Chief Executive Officer Sidar
Smiths Detection launches iCMORE algorithms for lithium batteries and dangerous goods for HI-SCAN 10080 XCT2.7.2020 11:00:00 CEST | Press release
Smiths Detection, a leading detection and security company, has launched iCMORE detection algorithms for lithium batteries and dangerous goods for use by its HI-SCAN 10080 XCT scanner, becoming its first explosive-detection system (EDS) to offer these options. The algorithms enhance the scanner’s detection capabilities by helping identify lithium batteries, flammable liquids and solids, and compressed and liquefied gasses, which can pose a risk should they ignite or explode. With iCMORE, Smiths Detection can now reliably and accurately detect potentially dangerous lithium batteries, alongside other dangerous goods, across both its conventional X-ray and its EDS technologies. The iCMORE lithium batteries and dangerous goods algorithms are complementary adaptions to existing screening technology. Although the screening of dangerous goods is not yet mandatory in hold-baggage and air-cargo screening, the increased level of safety for passengers, staff and assets is a key driver for the imp
EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated Acute Respiratory Distress Syndrome2.7.2020 10:00:00 CEST | Press release
EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, today announced that the U.S. Food & Drug Administration (FDA) has approved a randomized, double-blind, placebo-controlled Phase 3 clinical trial protocol to evaluate the safety and efficacy of intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS). Siltuximab is a monoclonal antibody that directly neutralizes interleukin (IL)-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions, including COVID-19. It specifically binds to IL-6, thereby inactivating IL-6 induced signalling. Lee Morley, Chief Executive Officer, EUSA Pharma, said:“Since the start of the pandemic, a growing body of evidence has been published highlighting that COVID-19 associated ARDS may exhibit features of systemic hyperinflammation, resulting from excessive cytokine production – the so-called ‘cytokine storm’ – wi
Deenova Multiplies its Pharmacy Automation Market Presence into 7 European Countries2.7.2020 09:34:00 CEST | Press release
Deenova reported today its 2020 step-by-step but relentless continued geographic expansion into Austria, Belgium, France, Germany, Portugal, Spain, and Switzerland, with three new and seasoned business development staff totaling 66 years of healthcare industry experience. Christophe Jaffuel, Deenova’s International Business Development Director, stated: “I am extremely pleased to add Carlos Duran (formerly from Becton Dickinson-Carefusion-Rowa), Thierry Geraud (previously from Becton Dickinson-Carefusion-Pyxis) and Hilmi Sunay (recently from Omnicell-Health Robotics and Arxium-IHS Riva) to an already strong Deenova sales team. These 3 extremely talented and experienced individuals joined Deenova because of its unique technology and business approach to R.O.I., and total service solutions proven in the health care industry. I was equally impressed with Deenova’s demonstrated results when I joined the company 6 months ago, witnessing first-hand how Deenova simultaneously improves patient
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom